EUVIMEDEUVIMED entdecken
Vergleichsstudie

Procalcitonin Doubling Time for Postoperative Monitoring of Medullary Thyroid Carcinoma: A Comparative Kinetic Analysis

Alfredo Campenni, Petra Petranović Ovčariček, Alberto Posabella, Rosaria M Ruggeri, Luca Giovanella

Clinical Endocrinology · 2026

DOI: 10.1111/cen.70147 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Endocrinology, 2026. Verfasst von Alfredo Campenni und 4 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine Unit, Biomedical, Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, Italy. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Procalcitonin, Carcinoma, Neuroendocrine, Calcitonin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Calcitonin doubling time (CT‐DT) is an established prognostic tool in medullary thyroid carcinoma (MTC), yet CT measurement can be affected by analytical variability and assay interference. Procalcitonin (PCT) has shown promise as a complementary biomarker, but data on PCT doubling time (PCT‐DT) remain scarce.

Methods

Longitudinal CT and PCT were measured using Elecsys immunoassays in 25 MTC patients followed for up to 24 months after thyroidectomy. Doubling times were estimated using log‐linear regression and a rolling‐window approach. Agreement was assessed using Spearman correlation, Bland–Altman analysis, and Cohen's κ across predefined DT categories.

Results

CT and PCT kinetics showed clear separation across response categories. In progressive disease, CT‐DT and PCT‐DT were strongly correlated with minimal systematic bias and substantial categorical agreement ( κ = 0.76). Short DT values clustered in structural incomplete responders.

Conclusions

PCT‐DT closely mirrors CT‐DT and may serve as a complementary kinetic marker in the postoperative monitoring of MTC, particularly when CT interpretation is uncertain; however, these findings should be considered exploratory and warrant confirmation in larger prospective cohorts before clinical implementation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsProcalcitoninCarcinoma, NeuroendocrineCalcitoninHumansFemaleMaleMiddle AgedAdultKineticsThyroidectomyPostoperative PeriodBiomarkers, TumorAged

Stichwörter der Autor:innen

calcitonindoubling timekineticsmedullary thyroid carcinomaprocalcitonin

Substanzen

ProcalcitoninCalcitoninBiomarkers, Tumor

Autor:innen und Institutionen

  • Nuclear Medicine Unit, Biomedical, Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, Italy.
  • Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia.
  • School of Medicine, University of Zagreb, Zagreb, Croatia.
  • Department of Surgery, Gruppo Ospedaliero Moncucco, Lugano, Switzerland.
  • Medical School, University of Basel, Basel, Switzerland.
  • Endocrinology Unit, Clinical and Experimental Medicine, University of Messina, Messina, Italy.

Zitieren

APA

Campenni, A., Ovčariček, P. P., Posabella, A., Ruggeri, R. M., & Giovanella, L. (2026). Procalcitonin Doubling Time for Postoperative Monitoring of Medullary Thyroid Carcinoma: A Comparative Kinetic Analysis. Clinical Endocrinology. https://doi.org/10.1111/cen.70147

Vancouver

Campenni A, Ovčariček PP, Posabella A, Ruggeri RM, Giovanella L. Procalcitonin Doubling Time for Postoperative Monitoring of Medullary Thyroid Carcinoma: A Comparative Kinetic Analysis. Clinical Endocrinology. 2026. doi:10.1111/cen.70147

BibTeX
@article{Campenni2026,
  author = {Campenni, Alfredo and Ovčariček, Petra Petranović and Posabella, Alberto and Ruggeri, Rosaria M and Giovanella, Luca},
  title = {Procalcitonin Doubling Time for Postoperative Monitoring of Medullary Thyroid Carcinoma: A Comparative Kinetic Analysis},
  journal = {Clinical Endocrinology},
  year = {2026},
  doi = {10.1111/cen.70147}
}
Kostenlos starten →